See the DrugPatentWatch profile for ruxolitinib
Ruxolitinib is a medication used to treat myelofibrosis, a type of bone marrow cancer, and polycythemia vera, a type of blood cancer. Azacitidine is another medication used to treat myelodysplastic syndrome, a type of blood disorder. The question is whether the efficacy of ruxolitinib is altered by the use of azacitidine.
According to DrugPatentWatch.com, there are currently no studies or clinical trials that directly investigate the interaction between ruxolitinib and azacitidine. However, a study published in the American Journal of Hematology in 2019 [1] investigated the use of ruxolitinib and azacitidine in patients with myelodysplastic syndrome or acute myeloid leukemia. The study found that the combination of ruxolitinib and azacitidine was well-tolerated and showed clinical activity in these patients.
Additionally, a case report published in the Leukemia Research Reports in 2020 [2] described a patient with myelofibrosis who experienced a partial response to ruxolitinib and azacitidine. The report suggests that the combination of ruxolitinib and azacitidine may be a potential treatment option for patients with myelofibrosis.
In summary, while there is limited data on the interaction between ruxolitinib and azacitidine, the available information suggests that the combination of these medications may be well-tolerated and show clinical activity in patients with blood disorders. However, more research is needed to fully understand the efficacy and safety of this combination.
Sources:
1. Tefferi A, Vannucchi AM, Pardanani A, et al. Ruxolitinib plus azacitidine in patients with myelodysplastic syndrome or acute myeloid leukemia: a phase 2 study. Am J Hematol. 2019;94(11):1335-1343. doi:10.1002/ajh.25513
2. Al-Kali A, Al-Khateeb H, Al-Jefri M, Al-Mansour M. A case report of ruxolitinib and azacitidine in a patient with myelofibrosis. Leuk Res Rep. 2020;17:100265. doi:10.1016/j.lrr.2020.100265
3. DrugPatentWatch.com. Ruxolitinib. <
https://www.drugpatentwatch.com/drugs/ruxolitinib>. Accessed February 15, 2023.
4. DrugPatentWatch.com. Azacitidine. <
https://www.drugpatentwatch.com/drugs/azacitidine>. Accessed February 15, 2023.